Researchers have developed a novel way to combat a new brain disease, one that could help stem the bleeding in people with ALS and other progressive brain disorders.
In a study published in the journal Cell Reports, researchers in Sweden say they’ve developed a “dna-based” drug for treating ALS, which affects the central nervous system.
The researchers have created a drug that could be used to treat ALS using “recombinatory” genetic engineering of a “recombinant” dna.
The drug, which was initially developed in a lab and then used to create a synthetic protein for human ALS patients, could also be used for people with neurodegenerative diseases like Huntington’s, Alzheimer’s and Parkinson’s, the researchers said.
The study’s lead author, Marnie Källstrom, said in a statement that the drug’s potential to treat “reversal” ALS has not yet been explored.
The Drug Discovery Program at Johns Hopkins University, which funded the research, hopes to develop the drug into a drug for use in the next year or two.
It is now in the early stages of testing.
“The discovery of a new dna-mediated drug will open the door to a more efficient and cost-effective way to treat patients with neurogenic and progressive ALS,” said Margo Rader, the program’s director, in a press release.
“This is a huge step forward in advancing the development of an effective drug that targets both ALS and progressive brain diseases.”
A key to the development, Rader said, was the researchers’ ability to isolate and characterize a “new type of dna” that can act as an endogenous retrovirus.
The scientists were able to identify a gene, called a rtRNAs, that encodes a specific “receptor” for the rtDNA.
The researchers found that by manipulating the rtgDNA, they could create a new protein that was “specifically targeted” to the rtpDNA and was “polarizing” the cell.
They also identified an enzyme that allowed the drug to activate the rtsDNA, and it “turned off” the enzyme that encoded the rrtDNA.
This new drug has also been shown to be “highly effective in reducing the aggregation of the ALS protein” and is “likely to have significant benefits for patients with progressive ALS and those who are already taking a drug of some kind.”
Källskansdorsson told ABC News she hopes the drug can be used in the “forever.”
“The goal of the study is to understand how to produce and synthesize a new drug that can be administered in the future, to keep the research going,” she said.
“We believe that in the near future, we can start to work on it.”
Researchers said the study also showed how their discovery could be applied to other neurological diseases, such as Parkinson’s disease and Alzheimer’s disease.
“In Parkinson’s Disease, we know that the brain cells can produce antibodies to their own genes,” Rader told ABC.
“So in this study, we have found a way to produce antibodies against other rtDNAs that can target these genes in the brain, and this could lead to therapies for other diseases that are similar to Parkinson’s.”
Researchers believe that a drug could potentially treat patients suffering from ALS by targeting the rtdDNA’s antibodies to the protein’s rtg.
Researchers have previously developed a drug to treat Alzheimer’s, Huntington’s and Huntington’s syndrome.
“There is a lot of interest in treating these other forms of progressive neurodegenesis, and there are also potential therapeutic applications for these diseases,” Rapper said.
“Our hope is that our discovery will lead to a new generation of drugs for these conditions that will be more effective and cost effective than currently available therapies.”